An expert in lipid research has called on the global scientific community to intensify efforts in studying lipid droplets (LDs) and their role in cancer biology especially hepatocellular carcinoma (HCC), as emerging findings show their potential as targets for innovative cancer therapies.
According to him, HCC, the most common primary liver cancer, and the fourth leading cause of cancer-related deaths worldwide, is partly driven by dysregulated lipid metabolism. This dysregulation he said is characterised by the excessive accumulation of lipid droplets (LDs) within hepatocytes.
In one of his recent research papers obtained by Tribuneonline, he highlighted that LDs, primarily store fat, play complex roles in tumor development, progression, and treatment resistance.
“Lipid droplets are far more than simple fat storage units; they are dynamic structures intricately involved in cellular processes that drive tumor growth and survival,” he emphasized.
In his paper, Otakhor explained that LDs contribute to cancer cell proliferation by storing essential lipids needed for membrane synthesis and energy production. Their unique functions allow cancer cells to withstand metabolic stress, providing them with the resilience required to grow rapidly even under adverse conditions.
“Lipid droplets support the energetic and biosynthetic needs of cancer cells, allowing them to thrive where normal cells might not,” he stated.
According to him, LDs serve as reservoirs of lipid signaling molecules that can influence key cancer-related pathways such as PI3K/Akt/mTOR and Wnt/β-catenin.
“These pathways are vital for cell growth, and their regulation positions LDs as central players in tumor progression and metastasis,” he said.
This dual role makes LDs an essential component of the cancer cell’s survival toolkit, contributing not only to growth but also to the spread of cancer.
LDs also regulate reactive oxygen species (ROS) levels within cells, a feature that can impact cancer cells differently depending on the environment. While high ROS levels can lead to cell death, lower levels may enable cancer cell survival, Otakhor notes.
“The dual role of lipid droplets in modulating ROS illustrates their versatility and complexity in cancer biology,” he pointed out.
Research into the role of LDs in cancer has highlighted their potential as therapeutic targets. Otakhor outlines strategies such as disrupting LD formation, enhancing lipid breakdown, and modifying lipid signaling to impair tumor growth. “By targeting LD-related proteins like small GTPases/perilipins or using diacylglycerol acyltransferase (DGAT) inhibitors, we can make strides in reducing cancer cell viability,” he suggested. Some of these strategies have shown promise in preclinical models, signaling new hope for treatment options.
Otakhor emphasizes the correlation between LD accumulation in tumor cells and poor patient prognosis. Tumors with high LD content often exhibit more aggressive behavior, he notes, urging further research into LD inhibition as a way to manage cancer more effectively. “A focus on LD accumulation could pave the way for better diagnostic markers and therapeutic approaches,” he advocated.
Beyond the energy reserves they provide, LDs also support lipid-mediated signaling, which can interfere with conventional cancer treatments. For instance, LDs can contribute to the development of resistance against chemotherapy and radiotherapy by shielding cancer cells from treatment-induced stress. Otakhor believes that understanding these mechanisms is essential for overcoming treatment resistance in cancer therapy. “If we can target how LDs help cancer cells withstand treatment, we may be able to enhance the effectiveness of existing therapies,” he asserted.
The discovery of LDs as multifunctional organelles is reshaping perspectives on lipid metabolism in cancer, Otakhor remarked. Once perceived as passive fat stores, LDs are now known to play active roles in cancer cell metabolism and resilience, helping to maintain cellular homeostasis in ways that benefit tumor cells.
“Lipid droplets are at the heart of cellular adaptation in cancer, highlighting their significance in both health and disease,” he commented.
Otakhor’s review aims to consolidate current understanding and identify gaps in knowledge that can guide future research. He suggests that investigating the biogenesis and regulation of LDs will be crucial in devising novel therapeutic interventions. “We must understand how lipid droplets form, interact, and function if we hope to leverage them in cancer treatment,” he urged.
Lipid droplets are a promising yet underexplored area in oncology, according to Otakhor. Their involvement in crucial cancer cell processes positions them as valuable targets for treatment, but much remains to be studied to fully comprehend their potential. “While we have made significant progress, the therapeutic promise of LDs in cancer is just beginning to be realized,” he stated.
Otakhor notes that collaboration across scientific fields could accelerate advancements in this area. He envisions a future where lipid droplets are not only better understood but are also integral to cancer diagnostics and therapeutics.
“Cross-disciplinary research is essential to unlock the full potential of LDs as both biomarkers and treatment targets,” he advised.
In highlighting the therapeutic promise of LDs, Otakhor emphasizes the need for more targeted research funding and support. He argues that the intersection of lipid metabolism and cancer biology represents a frontier that could bring about transformative advances in oncology.
“By investing in this research area, we can improve patient outcomes and broaden the scope of cancer treatments available,” he remarked.
“Understanding lipid droplets could be key to unlocking new pathways to combat this devastating disease,” he concluded.
ALSO READ THESE TOP STORIES FROM NIGERIAN TRIBUNE
US election: Trump declares victory as he addresses supporters
and then